Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

YAP1 expression drives chemotherapy resistance in small cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have discovered that some cancer cells express the YAP1 protein only after treatment with chemotherapy, allowing them to survive by becoming more invasive and leading to treatment resistance with eventual relapse in patients with small cell lung cancer (SCLC).

5 May 2026

65 % of eligible lung cancer patients do not receive the most appropriate targeted therapies, Diaceutics report finds

Diaceutics, the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, has released new research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer (aNSCLC) in the US are still not receiving the most appropriate treatment

From Diaceutics PLC 4 May 2026

Path-IO model predicts immunotherapy response in lung cancer patients

An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ability to accurately predict responses to immunotherapy for patients with metastatic non-small cell lung cancer (NSCLC).

21 Apr 2026

Why do the deadliest cancers still get less NIH research funding?

Researchers found that NIH funding for major US cancers does not consistently align with lethality, with highly fatal cancers such as pancreatic cancer and small-cell lung cancer receiving far less funding per estimated death than breast or prostate cancer. The study argues that incidence alone is not enough and that funding decisions should better incorporate mortality, survival, and mortality-to-incidence ratios.

21 Apr 2026

Scientists find unexpected immune pathways for mRNA cancer vaccines

The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic.

17 Apr 2026

New biochip detects tiny genetic markers in 20 minutes

A team of scientists from Nanyang Technological University, Singapore (NTU Singapore) has developed a new biochip that, when paired with Artificial Intelligence (AI), can detect quickly and accurately extremely small amounts of microRNAs, which are tiny genetic markers linked to diseases such as heart disease.

15 Apr 2026

Targeting super-enhancer mechanisms offers new strategies for cancer therapy

Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain malignancy, and create "transcriptional addiction" in cancer.

13 Apr 2026

Damon Runyon supports young scientists driving cancer research innovation

The Damon Runyon Cancer Research Foundation has named 13 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

11 Apr 2026

Lung tumors shift identity making treatment more difficult

A new study co-led by the Institute for Systems Biology (ISB) shows that some lung cancers can change identity as they evolve, shifting from one cancer type to another in ways that may make them more aggressive and harder to treat.

10 Apr 2026

Lactate modification fuels drug resistance and immune escape in cancer

Published in Current Molecular Pharmacology, a comprehensive review led by Yong Xu and colleagues from Shanghai Pulmonary Hospital explores the emerging role of lactylation, a post-translational modification driven by lactate, in lung cancer progression and drug resistance.

7 Apr 2026

COCOON trial protocol halves skin toxicities in lung cancer treatment

A new research perspective was published in Volume 13 of Oncoscience on March 11, 2026, titled "Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC."

3 Apr 2026

Targeted therapy pralsetinib improves outcomes in RET fusion-positive NSCLCs

In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth.

1 Apr 2026

Defining the limits of immunotherapy in early small-cell lung cancer

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international clinical trial, NRG-LU005, led by NRG Oncology in collaboration with the Alliance for Clinical Trials in Oncology. The results are published in the Journal of Clinical Oncology.

13 Mar 2026